2′-branched nucleosides and Flaviviridae mutation

US8674085B2 · kind B2 · utility

Assignees

• Idenix Pharmaceuticals LLC · US
• UNIVERSITÀ DEGLI STUDI DI CAGLIARI · IT

Inventors

• Jean-Pierre Sommadossi · Cambridge, US
• Paolo LaColla · Cagliari, IT
• David Standring · Milton, US
• Vadim Bichko · San Diego, US
• Lin Qu · Webster, US

Key dates

• Filing date: Oct 28, 2010
• Grant date: Mar 18, 2014
• Expiry date: Feb 14, 2031

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention discloses a method for the treatment of Flaviviridae infection that includes the administration of a 2′-branched nucleoside, or a pharmaceutically acceptable prodrug and/or salt thereof, to a human in need of therapy in combination or alternation with a drug that directly or indirectly induces a mutation in the viral genome at a location other than a mutation of a nucleotide that results in a change from serine to a different amino acid in the highly conserved consensus sequence, XRXSGXXXT (SEQ ID NO: 63), of domain B of the RNA polymerase region, or is associated with such a mutation. The invention also includes a method to detect a mutant strain of Flaviviridae and a method for its treatment.